Browsing: Access1

Agilent Technologies Inc. (NYSE: A) today announced the signing of a Memorandum of Understanding (MOU) with the Sarawak Infectious Disease Centre (SIDC) in East Malaysia.

Iron deficiency is present in 50% of the patients with heart failure and it is associated with worse symptoms and outcomes [1]. There have been a few studies analysing the benefit of intravenous (IV) ferric carboxymaltose in heart failure with iron deficiency. In the AFFIRM-AHF [2] trial, administration of IV ferric carboxymaltose reduced the risk of cardiovascular death and total hospitalisations for heart failure in patients hospitalized for acute heart failure.

A rare subtype of the world’s most common parasite, Blastocystis, has been found to produce a unique by-product of its…

In the past few years, there has been an expansion of indications for SGLT-2 inhibitors. Initially used as add-on therapy…

Dupilumab (Dupixent) by Sanofi has initially been marketed for the treatment of uncontrolled moderate-to-severe Atopic Dermatitis. Its indications have since…

In conjunction with Institut Kanser Negara’s (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening at government clinics and hospitals under the Projek Saringan Awal Paru-Paru (SAPU) programme. As a centre of excellence for cancer care in the country, IKN will be the first government institution in the country to implement this AI technology.

Cardiogenic shock is the leading cause of death amongst patients hospitalized with acute myocardial infarction. Immediate revascularization of the culprit lesion is the only treatment available but mortality still remains high. The use of extracorporeal life support (ECLS), which enables full circulatory and respiratory support, have increased with the aim to achieve haemodynamic stabilization in patients with severe or rapidly deteriorating infarct-related cardiogenic shock. 

From the first HIV medication approval in 1987, treatment for HIV has come a long way. With the help of…

In 2019, the global contraceptive use prevalence was found to be 51.9% [1]. However, there was a huge difference in…

IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with Tecentriq plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC)
IMbrella A data build on the previously reported IMpower133 trial, which was the first clinically meaningful advance in the treatment of ES-SCLC in more than twenty years